INmune announces initial results from Phase I/II trial of INKmune with mCRPC

INmune Bio continues to advance its Natural Killer, NK, cell therapy, INKmune, in a Phase I/II trial for men with metastatic Castration-Resistant Prostate Cancer, mCRPC. The Company is pleased to announce initial results from the first patient cohort in the trial. Blinded analysis of the monitoring blood samples from the first three patients showed changes in the phenotype and function of the patient’s NK cells. Although this is the lowest dose cohort, 2 of 3 patients showed an increase in circulating activated NK cells and all three showed increased NK cell function sustained for more than 40 days after the final INKmune infusion. One patient showed a transient 21% decrease in PSA associated with the increase in NK cell activity and function.